- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on NTRK Gene Fusion Overexpression
Total 56 results
-
Centre Leon BerardRecruitingCancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditionsFrance, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
-
Hoffmann-La RocheNo longer availableCancers With NTRK, ROS1, or ALK Gene FusionsUnited States
-
Jiangsu vcare pharmaceutical technology co., LTDCompletedLocally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionChina
-
BayerRecruitingLocally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionUnited States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
-
Jiangsu Simcere Pharmaceutical Co., Ltd.RecruitingAdvanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene FusionChina
-
BayerCompletedAdvanced or Recurrent Solid Tumor Harboring an NTRK Gene FusionJapan
-
BayerCompletedA Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat CancerSolid Tumors Harboring NTRK FusionUnited States
-
BayerApproved for marketingTumors Harboring NTRK Fusion
-
University of California, San FranciscoTerminatedALK Fusion Protein Expression | Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma | ROS1 Fusion Positive | BRAF wt Allele | Invasive Skin Melanoma | MET Fusion Gene Positive | NRAS wt Allele | NTRK1 Fusion... and other conditionsUnited States
-
BayerRecruitingAdvanced or Recurrent Solid Tumor Harboring an NTRK Gene FusionJapan
-
BayerCompleted
-
iOMEDICO AGRoche Pharma AGActive, not recruitingNTRK Family Gene MutationSwitzerland, Germany
-
BayerCompleted
-
BayerCompletedSolid Tumors Harboring NTRK FusionUnited States
-
Jin-Hee AhnAsan Medical CenterUnknownHER-2 Gene Amplification | HER-2 Protein Overexpression
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.UnknownSolid Tumor | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein OverexpressionChina
-
BayerNo longer availableSolid Tumors Harboring NTRK Fusion
-
Indonesia UniversityDr Cipto Mangunkusumo General HospitalCompletedin Vitro Fertilization | Acupuncture | Oocyte Maturation | BCL2 Gene mRNA OverexpressionIndonesia
-
BayerCompletedSolid Tumors Harboring NTRK FusionUnited States, Belgium, Italy, Germany, Australia, Spain, Singapore, Denmark, France, Ireland
-
BayerActive, not recruitingSolid Tumors Harboring NTRK FusionUnited States, China, Poland, Australia, Germany, Japan, Canada, Italy, Czechia, Spain, Turkey, United Kingdom, Sweden, Netherlands, France, Switzerland, Korea, Republic of, Denmark, Ireland, Israel, Ukraine
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingAdvanced Solid Tumors Harboring NTRK Fusion | Primary Central Nervous System Tumors Harboring NTRK FusionChina
-
St Vincent's Hospital, SydneyTerminatedSolid Tumor | Androgen Receptor Gene OverexpressionAustralia
-
Orum Therapeutics USA, Inc.RecruitingHER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein OverexpressionUnited States
-
BayerCompletedLocally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion | Infantile FibrosarcomaFrance
-
CHANGHEE LEEPurdue University; LG Electronics Inc.CompletedBCL2 Gene mRNA OverexpressionKorea, Republic of
-
Aristotle University Of ThessalonikiCompletedPoor Ovarian Response | Androgen Receptor Gene Overexpression | Normal Responders | Bologna Criteria
-
PlexxikonTerminatedSolid Tumor | Tenosynovial Giant Cell Tumor | Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion MutationsUnited States
-
Relay Therapeutics, Inc.Active, not recruitingCholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, AdultUnited States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
-
Sameek RoychowdhuryNational Cancer Institute (NCI)WithdrawnLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ALK Gene Mutation | Metastatic Malignant Neoplasm in the Brain | Advanced Malignant Neoplasm | ALK Fusion Protein Expression | Metastatic Malignant Neoplasm in the Central Nervous System | ROS1 Gene Mutation | ALK Gene... and other conditionsUnited States
-
University Health Network, TorontoBayer; AstraZeneca; Amgen; AnHeart Therapeutics Inc.; Applied Health Research Centre and other collaboratorsRecruitingCancer | Malignancies Multiple | Malignant Solid Tumor | Cancer, Therapy-Related | Molecular Sequence Variation | Genetic Alteration | Gene Fusion | Receptor Tyrosine Kinase Gene Mutation | RTK Family Gene Mutation | Ras (Kras or Nras) Gene MutationCanada
-
BayerActive, not recruitingSolid Tumors Harboring NTRK FusionUnited States, Korea, Republic of, China, Japan, India, France, Turkey, Portugal, Spain, Taiwan, Czechia, Sweden, Brazil, Denmark, Singapore, Argentina, Germany, Ireland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Eli Lilly and Company; Genentech, Inc.; Kazia... and other collaboratorsRecruitingMetastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | NTRK Family Gene Mutation | CDK Gene Mutation | PI3K Gene Mutation | ROS1 Gene Mutation | KRAS G12C MutationUnited States
-
Assiut UniversityUnknownDetection of PCM1-JAK2 Fusion Gene by FISH in the Two Types of t-MDS/AML and Relationship Between PCM1-JAK2 Fusion Gene and Cumulative Dose, Dose Intensity
-
Day One Biopharmaceuticals, Inc.RecruitingMelanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditionsUnited States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
-
TransThera Sciences (Nanjing), Inc.CompletedCholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Fusion | FGFR1 Alteration | FGFR3 AlterationUnited States
-
Taiho Oncology, Inc.RecruitingAdvanced Cholangiocarcinoma | FGFR2 Fusions | Gene RearrangementUnited States, Korea, Republic of, Spain, Japan, Portugal, Italy, China, Argentina, Brazil, Poland, Australia
-
Changhoon YooCompletedCholangiocarcinoma | Biliary Tract Cancer | HER-2 Gene Amplification | HER-2 Protein OverexpressionKorea, Republic of
-
Istituto Scientifico Romagnolo per lo Studio e...TerminatedEstrogen Receptor Positive Breast Cancer | Androgen Receptor Gene Overexpression | Progesterone Receptor Positive Tumor | Metastatic Breastcancer | Estrogen Receptor Negative Neoplasm | Progesterone Receptor Negative NeoplasmItaly
-
University of California, IrvineApplied Biology, Inc.WithdrawnCovid19 | Androgen Receptor Gene OverexpressionUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedBreast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | HER-2 Gene Amplification | Breast Cancer Female | HER2 Positive Breast Carcinoma | HER-2 Protein OverexpressionUnited States
-
Bellicum PharmaceuticalsSuspendedHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein OverexpressionUnited States
-
Ikena OncologyRecruitingSolid Tumor | Solid Tumors, Adult | Malignant Pleural Mesothelioma (MPM) | Epithelioid Hemangioendothelioma (EHE) | NF2 Deficient Mesothelioma | Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes | NF2 Deficiency | YAP1 or TAZ Gene FusionsUnited States, United Kingdom
-
University of MichiganNational Cancer Institute (NCI)CompletedThyroid Cancers That Contain the PAX8-PPARgamma Fusion GeneUnited States
-
Morten Mau-SørensenOdense University Hospital; Aarhus University Hospital; Aalborg University HospitalRecruitingEsophageal Squamous Cell Carcinoma | HER-2 Gene Amplification | HER-2 Protein OverexpressionDenmark
-
Northwell HealthRecruitingGlioblastoma | Brain Cancer | Brain Tumor | GBM | Brain Neoplasm | Brain Neoplasm, Malignant | EGFR Gene OverexpressionUnited States
-
Peking University Cancer Hospital & InstituteCompletedBreast Neoplasms | Neoplasm Metastasis | Immunotherapy | Gene Expression ProfilingChina
-
Shanghai General Hospital, Shanghai Jiao Tong University...Not yet recruitingTo Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)
-
William ShomaliIncyte CorporationRecruitingEosinophilia | Hypereosinophilic Syndrome | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Splenomegaly | Hepatomegaly | Chronic Eosinophilic Leukemia, Not Otherwise Specified | JAK2 Gene Mutation | BCR-JAK2 Fusion Protein Expression | Blasts 20 Percent or Less of Peripheral Blood White... and other conditionsUnited States
-
Oncoethix GmbHCompletedTriple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Castrate-resistant Prostate Cancer | CRPC | NUT Midline Carcinoma | Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingObesity | Overweight | Ductal Breast Carcinoma In Situ | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Premalignant LesionUnited States